PRESENTATION

H1 FY2023 — Results presentation

H1 FY2023PDF · 71 pages4.3 MB
for the six months ended 31 December 2022

-- 1 of 71 --

2
2 Y E A R S 1 0 Y E A R S
Global risks interconnection map	Global risks ranked by severity over the short and long term
GLOBAL RISK LANDSCAPE
High
Medium
Low
Nodes
Risk influence
Edges
Relative influence
High
Medium
Low
Prolonged economic
downturn
Adverse outcomes of
frontier technologies
Digital power concentration
Digital inequality
Breakdown of critical information
infrastructure
Widespread cybercrime
and cyber security
Terrorist attacks
Misinformation &
disinformation
Use of weapons of
mass destruction
Interstate
conflict Geoeconomic
confrontation
Ineffectiveness of
multilateral institutions
Environmental
damage incidents
Failure to mitigate
climate change
Biodiversity loss &
ecosystem collapse
Natural resource
crisis
Failure of
climate-change
adaption
Collapse of systematically
important supply chain
Natural disasters &
extreme weather
Large-scale
involuntary
migration
State collapse
Proliferation of illicit
economic activity
Chronic health conditions
Employment crises
Failure to stabilize price trajectories
Debt crises
Cost of
living crises	Asset
bubble
burst
Erosion of social cohesion
Severe mental health
deterioration
Infectious diseases
Collapse or lack of public
infrastructure and services
Geopolitical Societal Technological	Economic Environmental	Risk categories
Cost-of-living crisis	1
Natural disasters and extreme
weather events	2
Geoeconomic confrontation	3
Failure to mitigate climate change	4
Erosion of social cohesion and
societal polarisation	5
Large-scale environmental
damage incidents	
6
Failure of climate change adaption	7
Widespread cybercrime and
cyber insecurity	8
Natural resources crises	9
Large-scale involuntary migration	10
Failure to mitigate climate change	1
Failure of climate change adaption	2
Natural disasters and extreme
weather events	3
Biodiversity loss and ecosystem collapse	4
Large-scale involuntary migration	5
Natural resources crises	6
Erosion of social cohesion and
societal polarisation	7
Widespread cybercrime and cyber
insecurity	8
Geoeconomic confrontation	9
Large-scale environmental
damage incidents	10
Geopolitical Societal Technological	Economic Environmental	Risk categories

-- 2 of 71 --

3
GLOBAL
Normalised
operating profit
Core new
business
+15%
to R11 061m
+22%
to R5 930m
Normalised
headline earnings
+30%
to R3 747m
Headline
earnings
-9%
to R2 981m
Excluding discontinued products
like VitalityInvest and Ping An
Health reinsurance business
Total income from
non-insurance
+51%
to R2 528m

-- 3 of 71 --

4
GLOBAL
Core new
business
+15%
to R11 061m
Normalised
headline earnings
+30%
to R3 747m
Headline
earnings
-9%
to R2 981m
1
2
3
Evolving the model to create a platform for strong future growth
Strong growth in quality earnings, driven by the efficacy of the Vitality
shared-value model and in line with the target operating model
Focus on financial prudence and immunisation from a volatile interest rate
environment
4
Strong performance removes need for VCP; and given strong growth dynamics
a dividend is premature but will be revisited at the end of the financial year
Normalised
operating profit
+22%
to R5 930m
Total income from
non-insurance
+51%
to R2 528m

-- 4 of 71 --

5
ESTABLISHED
EMERGING
NEW
Organic Growth ModelVitality Shared-value
business modelModel remains
resilient in face of
evolving global
trends
NATURE
OF RISK TECHNOLOGY
SOCIAL
RESPONSIBILITY
For our clients:
• Better value
• Improved health and behaviour outcomes
For our businesses:
• Product differentiation and competitive
advantage
• Superior growth
• Better persistency
• Lower mortality/claims
• Superior operating profit growth (CPI
+ 10%)
• No recourse to additional capital
• Ensuring shareholder value created
• Capital strength, liquidity and return
on capital
THE DYNAMICS OF THE BUSINESS AND OPERATING MODELS
L E A D S T O :
Customer engagement,
superior lapses and
mortality experience
Operating profit growth of
CPI+10% with new
business growth
New initiative materiality
and progress
Capital strength and
appropriate cash
generation

-- 5 of 71 --

6
Health 1 825 +4% 4 442 +23% 693 +18%
Life 2 518 +30% 1 485 +17%
Invest 592 +15% 1 505 -1%
Insure 4 -73% 616 +3%
Bank -398 -20% 706 +71%
Other SA New -148 -15% 356 -21%
SA 4 414 +23% 8 566 +15% 1 399 +40%
Vitality Health 867 +2% 890 +26%
Vitality Life 536 +48% 801 +45%
UK New -126 +17%
UK 1 277 +15% 1 691 +34%
Vitality Network 199 +52%
VHI - Ping An Health1 84 -40% 804 -12%
VHI - Other -44 -51%
VG 239 +33% 804 -12% 1 1292 +69%
Strong new business growth, profit impacted by once-off costs
Excellent growth with Individual Life up 11% and a recovery in Group Life
Robust despite weak market performance
Continued elevated claims experience
Profit sustained off a high base despite excellent new business growth
Excellent growth driven by strong operating variances
Strong growth from deepened partner relationships
Tough market conditions, however business fundamentals remain strong
Continued growth in clients and increasing share of new credit card credit
Amplify Health made first acquisition
Operating loss impacted by run-down cost of VitalityInvest
New business impacted by a large scheme transfer into UF in prior period
STRONG OPERATING PERFORMANCE
Operating profit New business
1 PAH own licence 2 VG income excludes cost recoveries and rewards
+22%	R5 930m +15%	R11 061m	Total Excl products in run down
Income
+51%	R2 528m
ZARm

-- 6 of 71 --

7
STRONG OPERATING PERFORMANCE
Total income from non-
insurance business lines
R2 528m
Operating profit
R5 930m Core new business API
R11 206m
-
1 000
2 000
3 000
4 000
5 000
6 000
H1 2004	
H1 2005	
H1 2006	
H1 2007	
H1 2008	
H1 2009	
H1 2010	
H1 2011	
H1 2012	
H1 2013	
H1 2014	
H1 2015	
H1 2016	
H1 2017	
H1 2018	
H1 2019	
H1 2020	
H1 2021	
H1 2022	
H1 2023
 -
2 000
4 000
6 000
8 000
10 000
12 000
H1 2004	
H1 2005	
H1 2006	
H1 2007	
H1 2008	
H1 2009	
H1 2010	
H1 2011	
H1 2012	
H1 2013	
H1 2014	
H1 2015	
H1 2016	
H1 2017	
H1 2018	
H1 2019	
H1 2020	
H1 2021	
H1 2022	
H1 2023
 -
500
1,000
1,500
2,000
2,500
3,000
H1 2020 H1 2021 H1 2022 H1 2023
Rm	Rm	Rm
18%
CAGR from 2004
11%
CAGR from 2004

-- 7 of 71 --

8
NEW INITIATIVE SPEND REVERTED TO TARGET
Investment in New reverted to guidance
% core operating profit (UK includes VitalityInvest)
Amplify Health had strong profits offsetting other VG
New; excluding this, majority of New is in Bank and VG
VG New
Excl
Amplify
Health
Amplify
Health
Total VG
New
Mainly made up of Vitality USA and V1
Breakdown of New (excl Amplify
Health and VitalityInvest)
Breakdown of VG New
UK 52%
19%
SA other
27%
VG excl Amplify
Health
2%
UK excl
VitalityInvest
11%
0%
5%
10%
15%
20%
25%
H1 2019 H1 2020 H1 2021 H1 2022 H1 2023

-- 8 of 71 --

9
UNIQUE ABILITY TO ENGAGE CLIENTS
Duration
Engagement improves over time
Quality
Engagement beyond just activity
Scale
High engagement across markets
0% 20% 40% 60% 80% 100%
Market 1
Market 2
South Africa
Market 3
Market 4
Market 5
Market 6
United Kingdom
Market 7
Market 8
Market 9
Market 10
Market 11
Market 12
Market 13 0.9
1.0
1.1
1.2
1.3
1.4
1.5
1.6
1.7
Month 1 Month 6 Month 12 Month 24
Engagement index across all markets
-100% -50% 0% 50% 100%
Market 1
Market 2
Market 3
Market 4
Market 5
Market 6
Market 7
Market 8
Market 9
Market 10
SA
UK
Market 11
Market 12
Market 13
Non-physical activity	Physical activity

-- 9 of 71 --

10
SIGNIFICANT STATUS CORRELATIONS
Lapses
No VD
Blue
Bronze
Silver
Gold
Diamond
No VD
Blue
Bronze
Silver
Gold
Diamond
None
Blue
Bronze
Silver
Gold
Diamond
Deposits
Arrears 94%
Lower
arrears rate
9x
Higher
average
deposits
43%
Lower
paid-ups
70%
Lower
withdrawals
55%
Lower claims
77%
Lower lapses
15%
Lower claims
45%
Lower lapses
38%
Lower claims
55%
Lower lapses
None
Blue
Bronze
Silver
Gold
Diamond
Claims
Life insurance Health insurance Motor insurance Long-term savings Banking
Blue
Bronze
Silver
Gold
Blue
Bronze
Silver
Gold
Blue
Bronze
Silver
Gold
Blue
Bronze
Silver
Gold
Blue
Bronze
Silver
Gold and	
Diamond
Blue*
Bronze
Silver
Gold and	
Diamond

-- 10 of 71 --

11
GROUP EMBEDDED VALUE
Group revenue
attributable to
Emerging and New
28%	14.4%
Annualised ROEV
Opening EV VNB Unwind of
discount rate
Non-economic
experience
variances and
methodology
and
assumption
changes
Operational EV Economic
experience
variances &
methodology &
assumption
changes
Other Closing EV
R92 459m
R93 986m
R86 258m
Operational EV Economic and other
Positive non-economic
experience variances
Total
Lapses* 171
Renewal expenses 71
Mortality and morbidity 320
Premium and Fee
Income 239
Inflation-linked
indexation 393
Other 609
Total 1 803
*Lapses, surrenders and policy alterations

-- 11 of 71 --

12
EXCESS SHAREHOLDER CASH GENERATION WAS USED TO REPAY DEBT
R7.5bn
Cash generated
from in-force
(R6.9bn)
Cash used net of
finre funding
Cash
generated
from in-force
business
R7.5bn
-R1.0bn
Tax
-R4.5bn
New
business net
finre
-R0.8bn
New Initiatives
-R0.8bn
Finance costs
and dividends
Cash
generated
Cash
used
R552m
Vitality
Life
Vitality
Health
Discovery
Life and
Invest
Discovery
Health
Net cashflow
before paying
debt
Decision to repay debt given excess shareholder cash generation	Businesses generate
sufficient cash
R0.6bn
Net cash before debt
Cash conversion1
1 Normalised operating profit after tax over cash generated from operations less spend on new business less tax before business development spend
0%
10%
20%
30%
40%
50%
60%
70%
H120 H121 H122 H123

-- 12 of 71 --

13
CASH GENERATION RECOVERING AND WELL CAPITALISED
Strongly capitalised	FLR within target
DHMS solvency
(unaudited)
35.1%
Dec 21
Cover
Dec 22
Cover
Life 1.8x 1.8x
Insure 1.8x 1.4x
VH 1.9x 1.5x
VL 2.2x 2.2x
Bank1 1.4x 1.2x
PAH2 2.1x 2.7x
1 Capital Adequacy Ratio
2 Comprehensive Solvency Ratio, definition set by China Banking and Insurance Regulatory Commission
3 Centre cash + undrawn committed facilities
Cash generation recovery
Cash generated before dividends
and debt and excl. shares issued
and once-off’s (R millions)
18%
20%
22%
24%
26%
28%
30%
FY17
H1 18
FY18
H1 19
FY19
H1 20
FY20
H1 21
FY21
H1 22
FY22
H1 23
FLR
22%
28%
( 800)
( 600)
( 400)
( 200)
0
200
400
600
800
H1 20 H1 21 H1 22 H1 23
Sufficient liquidity
0
500
1,000
1,500
2,000
H1 FY21 H1 FY22 H1 FY23
Centre liquidity3 , R millions

-- 13 of 71 --

14
GIVEN GROWTH DYNAMICS, PREMATURE TO REINSTATE DIVIDEND
Theoretical dividend framework The COVID-19 period
(2020 – 2022)
Current period under review
%
operating
profit
Dividend
cover
ESTABLISHED
EMERGING
NEW
90%
20%
-10%
Philosophy
Funded
from the
dividend
In line
with
market
No
dividend
-1x
Dividend
cover
~ 4x
2-3x
0x
• Investment in New
c20%, mainly DSY
Bank
R5 930m
18%
23%
28%
FY20 H121 FY21 H122 FY22 H123
0%
10%
20%
H1 2019 H1 2020 H1 2021 H1 2022 H1 2023
FY22 FY23 FY24 FY25 FY26 FY27
Before new business
acquisition cost
Profit before tax
• Dividend paused
• Desire to reduce
debt
• R1.5bn Ping An Health
capital injection
Operating profit
Prudence
Growth
H1 2002	
H1 2003	
H1 2004	
H1 2005	
H1 2006	
H1 2007	
H1 2008	
H1 2009	
H1 2010	
H1 2011	
H1 2012	
H1 2013	
H1 2014	
H1 2015	
H1 2016	
H1 2017	
H1 2018	
H1 2019	
H1 2020	
H1 2021	
H1 2022	
H1 2023
R552m
Cashflow before
debt repaid
26% to 22%
Financial leverage
ratio
21% to 11%
Invested in New
CY 23
Bank monthly
operational break-even
(upside scenario)
• Immunised against
interest rate
volatility
(1 000)
( 500)
0
500
1 000
H1 20 H1 21 H1 22 H1 23

-- 14 of 71 --

15
CASH USED TO INVEST IN FUTURE GROWTH
R7.5bn
Cash generated
from in-force
(R6.9bn)
Cash used net of
finre funding
R0.6bn
Net cash flow
before debt
Cash
generated
from in-force
business
R7.5bn
-R1.0bn
Tax
-R4.5bn
New business
net finre
-R0.8bn
New Initiatives
-R0.8bn
Finance costs
and dividends
Cash
generated
Cash
used
R552m
Vitality
Life
Vitality
Health
Discovery
Life and
Invest
Discovery
Health
Net cashflow
before paying debt
New business
IRR*
RFR + 9.4%
*Weighted average RFR across the Group
1
2
VS

-- 15 of 71 --

16
REPORTED PROFIT AFFECTED BY INTEREST RATES
Rm 6 months ended
Dec 2022
6 months ended
Dec 2021 %
Normalised profit from operations before economic assumptions adjustments 5,930 4,872 +22%
Economic assumptions adjustment DL -862 498
Economic assumptions adjustment VL -38 -46
Time value of money of VitalityLife interest rate swaption -86 60
Forex and gains/(losses) on foreign exchange contracts not designated as a hedge 30 227
Finance charges excl. 1DP finance lease -792 -698
Vaccination costs 0 -137
Other (including IFRS reporting adjustments) 68 -55
Profit before tax 4,250 4,721 -10%
Tax -1,307 -1,416
Profit attributable to preference shareholders -31 -28
Headline earnings adjustment 69 1
Headline earnings 2,981 3,278 -9%
Economic assumptions adjustment (DL and VL) after tax and hedging 659 -321
Other 107 -81
Normalised headline earnings 3,747 2,876 +30%

-- 16 of 71 --

17
INTEREST RATES IMPACT EARNINGS, BUT NO IMPACT ON OPERATIONS
Interest rate volatility Earnings Liquidity Solvency
Discovery Life
VitalityLife
0%
5%
10%
15%
0 4 8 12 16 20 24 28 32 36 40 44 48	
Annualised Spot Rate
Years from valuation
Nominal Spot Rate Curve
Jun 22 JSE
(cash flow weighted
single rate 12.25%)
Dec 22 JSE
(cash flow weighted
single rate 11.75%)
1 Year to date economic assumption impact on IFRS earnings before discretionary margin changes
2 weeks
prior
Valuation
Date
2 weeks
after
cR400m
Relative gain
cR600m
Relative gain
IFRS earnings impact1 sensitive
to level and shape of yield curve
*Nominal and real rates
0.5%
drop*
Base 0.5%
increase*
Cashflow immaterially
impacted by changes in rates
(assuming constant CPI)
Shape of yield curve changed, particularly
at long end
Solvency coverage
immaterially impacted
0.5%
drop*
Base 0.5%
increase*
*Nominal and real rates
Hedge limits downside to rates
falling and upside in margins
Hedge protects against large
negative cashflow risk
VLL solvency resilient to stresses
25 Year SONIA swap rate
Significant interest rate volatility
-200
-100
-
100
200
1.0%
1.3%
1.6%
1.9%
2.2%
2.5%
2.8%
3.1%
3.4%
3.7%
4.0%
4.3%
4.6%
4.9%
5.2%
5.5%
Cashflow with hedge
Cashflow with no hedge
0%
100%
200%
300%
No Hedge With Hedge
-200
-150
-100
-50
0
50
100
1.0%
1.3%
1.6%
1.9%
2.2%
2.5%
2.8%
3.1%
3.4%
3.7%
4.0%
4.3%
4.6%
4.9%
5.2%
5.5%
Margin Generated with Hedge
IFRS with hedge
IFRS with no hedge
Margin Generated with no hedge
0%
1%
2%
3%
4%
5%
31/12/19	
29/02/20	
30/04/20	
30/06/20	
31/08/20	
31/10/20	
31/12/20	
28/02/21	
30/04/21	
30/06/21	
31/08/21	
31/10/21	
31/12/21	
28/02/22	
30/04/22	
30/06/22	
31/08/22	
31/10/22

-- 17 of 71 --

18
GLOBAL
Normalised
operating profit
Core new
business
+15%
to R11 061m
+22%
to R5 930m
Normalised
headline earnings
+30%
to R3 747m
Headline
earnings
-9%
to R2 981m
Excluding discontinued products
like VitalityInvest and Ping An
Health reinsurance business
Total income from
non-insurance
+51%
to R2 528m

-- 18 of 71 --



-- 19 of 71 --

20
VITALITY PLATFORM

-- 20 of 71 --

21
USING CAUSAL INFERENCE WITH NOVEL INSIGHTS
502 062
members
Study over
2013 - 2019
Causal
Forest
Death (𝑡2)
(Outcome)
Physical activity
points (𝑡1)
(Treatment)
Age
(𝑡0)
Vitality Status
(𝑡0)	Duration on
Vitality
Total Claims
(𝑡0)
RUB
(𝑡0)
Socio-
economic
score
(𝑡0)
Chronic
Count
(𝑡0)
PA Points per Week
(𝑡0)
Isolating the impact of exercise Key insights: how exercise reduces risk
-36% -40% -49%
-80%
-30%
20%
0 (base) Low Medium High
-27%
-50% -61%
-100%
-50%
0%
0 (base) Low Medium High
Age 45-65
Age 65+
Relative Mortality
Relative Mortality
12%
-44% -55%
-100%
-50%
0%
50%
0 Base Medium High
Relative Mortality
Age 45-65
Impact of PA
increases as
you get older
Maintenance is
important for
already active
members
Significant
improvements
as PA increases
36.6bn exercise
points earned
-15%
-67% -60%
-80%
-60%
-40%
-20%
0%
0 (base) Low Medium High
-56%
-63% -63%	-65%
-60%
-55%
-50%
0 (base) Low Medium High
Unadjusted mortality
Age 45-65
Age 65+
Includes selection and
behaviour change

-- 21 of 71 --

22
HABIT INDEX PREDICTS LONG-TERM BEHAVIOUR CHANGE
Classify habits and analyse
transitions over time
Deeper understanding of the
value equation	Identify habit
Time
Habit formation
Look back x
weeks and
establish overall
habit
Generate a habit index
that changes over time
based on exercise
patterns
𝐻𝐼 = 𝑅2 × 𝐸𝑝𝑤
Exercised
Did not exercise
Track how member exercises over 7-week
period
Strong
Weak
Bad Good
Habit Strength
Habit type
∆ 𝑉𝑎𝑙𝑢𝑒
=
∆ 𝑞𝑥
∆ ℎ𝑎𝑏𝑖𝑡 × ∆ ℎ𝑎𝑏𝑖𝑡
𝑟𝑒𝑤𝑎𝑟𝑑 − ∆ 𝑝𝑟𝑒𝑚𝑖𝑢𝑚
Observe a net positive habit
improvement over time
Persistency and strength of habit
determines value created
6 weeks of behaviour is
enough to establish a habit

-- 22 of 71 --

23

-- 23 of 71 --

24
THREE STRATEGIC STRANDS

-- 24 of 71 --

25
Discovery Insure	
Discovery Life	
Discovery Invest	
Discovery Bank	
Discovery Health
New business
+15%
to R8 566m
Operating profit
+23%
to R4 414m

-- 25 of 71 --

26
Discovery Insure	
Discovery Life	
Discovery Invest	
Discovery Bank	
Discovery Health

-- 26 of 71 --

27
H1
FY20
H2
FY20
H1
FY21
H2
FY21
H1
FY22
H2
FY22
H1
FY23
Jul-19
Dec-19	
May-20	
Oct-20	
Mar-21	
Aug-21	
Jan-22	
Jun-22	
Nov-22
DISCOVERY BANK
Net income Retail deposits Advances Operating result
>1.3m R12.7bn R4.8bn -R398m
Jul-19
Dec-19	
May-20	
Oct-20	
Mar-21	
Aug-21	
Jan-22	
Jun-22	
Nov-22
Jul-19
Dec-19	
May-20	
Oct-20	
Mar-21	
Aug-21	
Jan-22	
Jun-22	
Nov-22
Total
clients
>580k
*Includes capital development costs during build phase
-700
-600
-500
-400
-300
-200
-100
0
H1
FY19*
H1
FY20
H1
FY21
H1
FY22
H1
FY23
New Business Acquisition Costs
Loss excl. new business
acquisition costs
+51% vs
H1 FY22
+66% vs
H1 FY22
+33% vs H1 FY22 +19% vs H1 FY22
R706m
+71% vs H1 FY22
Total
accounts
Graph shows total clients

-- 27 of 71 --

28
SIGNIFICANT GROWTH
± 1000 daily new business
sales
Average daily new business sales per
business day
Superior new business
product mix
Increasing % of new business weighted
towards Credit Card and Suite
0
100
200
300
400
500
600
700
800
900
1000
Q1
FY21
Q2
FY21
Q3
FY21
Q4
FY21
Q1
FY22
Q2
FY22
Q3
FY22
Q4
FY22
Q1
FY23
Q2
FY23
Incl. Jan 23
H1 FY22
H1 FY23
17%
38%
35%
10%
14%
40%
28%
18%
Savings PAYT Bundled CC and Suite
Increasing engagement/NIR
by tenure
NIR pcpm for different products
Indexed to month 1
378%
177%
139%
80%
100%
120%
140%
160%
180%
200%
220%
1 2 3 4 5 6 7 8 9 10 11 12
PAYT Bundled CC and Suite
Opportunity to increase
overall revenue
Revenue pcpm vs Big 4
400%
180%
160%
140%
120%
100%
80%
0
50
100
150
200
250
300
350
400
450
DSY
Bank 1
Bank 2
Bank 3
Bank 4
DSY
Average Big 4
NIR pcpm Overall
Revenue
pcpm
Big 4 Average

-- 28 of 71 --

29
EXCEPTIONAL CLIENT QUALITY
Income distribution of new business
Increasing % of higher income earners
H1 FY22
H1 FY23
37%
50%
10% 3%
New credit card market share
5%
15%
Q1
FY 21
Q3
FY21
Q1
FY22
Q3
FY22
Q1
FY23
Growing new credit market share Superior and improving credit
quality
Credit loss ratio vs market
1.8%
5.3%
Q2
FY21
Q3
FY21
Q4
FY21
Q1
FY22
Q2
FY22
Q3
FY22
Q4
FY22
Q1
FY23
Q2
FY23
Big 4
ave*
30%
50%
14%
7%
0-10k 10k-50k 50k-100k R100k+
Income per month June 2022

-- 29 of 71 --

30
ECONOMICS OF GROWTH
Operating leverage
Indexed to FY22 Q1
66%
107%
45%
Q1
FY22
Q2
FY22
Q3
FY22
Q4
FY22
Q1
FY23
Q2
FY23
Expenses pcpm Gross NIR pcpm Loss before tax pcpm*
*Once-off adjustments allocated evenly over the financial year
1.0
1.2
1.5 1.5 1.5
Blue Bronze Silver Gold Diamond
Banking vs insurance growth
Estimated trajectory of client growth rebased at 100
High value derived from more
engaged clients
NIR pcpm after cost of incentives by status
Indexed to Blue VM status
0
1000
2000
3000
4000
5000
6000
7000
1 2 3 4 5 6 7 8 9 10
Time since launch
Average financial services company illustrative
Discovery Bank actual	Discovery Bank illustrative

-- 30 of 71 --

31
-0.5
-
0.5
1.0
1.5
2.0
(0.15)
(0.10)
(0.05)
-
0.05
0.10
0.15
0.20
0.25
0.30
Jul-22
Sep-22	
Nov-22	
Jan-23	
Mar-23	
May-23
Jul-23
Sep-23	
Nov-23	
Jan-24	
Mar-24	
May-24
Jul-24
Sep-24	
Nov-24	
Jan-25	
Mar-25	
May-25
Jul-25
Sep-25	
Nov-25	
Jan-26	
Mar-26	
May-26
Jul-26
Sep-26	
Nov-26	
Jan-27	
Mar-27	
May-27
Clients Profit before tax (Base) Profit before tax (Upside)
-0.5
-
0.5
1.0
1.5
2.0
(0.10)
(0.05)
-
0.05
0.10
0.15
0.20
0.25
0.30
0.35
Jul-22
Sep-22	
Nov-22	
Jan-23	
Mar-23	
May-23
Jul-23
Sep-23	
Nov-23	
Jan-24	
Mar-24	
May-24
Jul-24
Sep-24	
Nov-24	
Jan-25	
Mar-25	
May-25
Jul-25
Sep-25	
Nov-25	
Jan-26	
Mar-26	
May-26
Jul-26
Sep-26	
Nov-26	
Jan-27	
Mar-27	
May-27
ATTRACTIVE RETURNS AND PROFITABILITY
Business case sensitivities:
R1bn-R1.2bn p.a. operating profit in 3 years
Key financial levers
Average income
pcpm
(Rands)
Expenses growth
(%; current references yoy
normalised growth; base/upside
references medium-term CAGR)
Model efficacy: CLR
(%, excl. overlays)
Growth: clients and
daily new business
(*average daily new business)
Economics to generate
R1bn-R1.2bn p.a in 3 years
Advances pc
(Rands)
1k*
1k* ±1.4k*
0
500
1,000
1,500
2,000
Current Base Upside
0
8,000
16,000
24,000
32,000
Current Base Upside
0
100
200
300
Current Base Upside
2.0%
2.5%
3.0%
Current Base Upside
0%
5%
10%
Current Base Upside
Operating profit (Rm)
Forward looking information on this slide is for illustration and has not been reviewed or reported on by the auditors
Operating profit (Rm)
Operating profit before tax and new business acquisition costs p.m.
Operating profit before tax p.m.
R100 million
R100 million
Base
Upside
Clients (m)
Clients
 (m)

-- 31 of 71 --

32
Discovery Insure	
Discovery Life	
Discovery Invest	
Discovery Bank	
Discovery Health

-- 32 of 71 --

33
DISCOVERY HEALTH
Membership New business Non-scheme growth Operating profit
>3.8m +23% >290k +4%
lives under administration to R4 442m lives to R1 825m
1993
1996
1999
2002
2005
2008
2011
2014
2017
2020
Non Scheme Products
Restricted Schemes
DHMS
Jan-18	
Jul-18	
Jan-19	
Jul-19	
Jan-20	
Jul-20	
Jan-21	
Jul-21	
Jan-22	
Jul-22
Flexicare
Gap Cover
Healthy Company
H1
2019
H1
2020
H1
2021
H1
2022
H1
2023
H1
2019
H1
2020
H1
2021
H1
2022
H1
2023
15%
of total revenue

-- 33 of 71 --

34
0%
2%
4%
6%
8%
10%
12%
2018 2019 2020 2021 2022
DHMS
DISCOVERY HEALTH MEDICAL SCHEME (DHMS) PERFORMANCE SUMMARY
Membership Stable plan movements and lapses
market share	57.6%
Stable lapses
5.5%
Plan upgrades / downgrades
1
DHMS Rest of
Industry
Others
Annualised lapse rate excludes turnover members: i.e. members from existing employer
groups who leave their employment and are subsequently replaced
Robust growth
Gross lives Withdrawing Lives
Left employer
Affordability
Provider change
Death
Emigration
Other
Movement to dependant
~338k lives
~312k lives
Gross activations and withdrawing lives
in 2022
94.6%
2.9% 2.5%
94.5%
2.6% 2.9%
94.6%
2.4% 3.0%
96.5%
1.9% 1.6%
2018: 2019: 2020:
2021: 2022:
97.1%
1.6% 1.3%

-- 34 of 71 --

35
SOLVENCY BUILT UP | PROTECTING MEMBERS AND THE SCHEME
Illustrative example based on sample scheme that was priced correctly for an operating breakeven in 2019
Solvency position Cost curve
Indexed at January 2019
-40%
-30%
-20%
-10%
0%
10%
20%
30%
40%
50%
60%
2019 2020 2021 2022 2023 2024 2025 2026
Solvency Required solvency
Healthcare discontinuities during
COVID-19 caused a reserve build up
What options are available
to manage the excess
solvency?
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
1.8
2.0
2019 2020 2021 2022 2023 2024 2025
Underlying medical cost
inflation = 10%
~(CPI+4%)

-- 35 of 71 --

36
SOLVENCY BUILT UP | PROTECTING MEMBERS AND THE SCHEME
SCENARIO 1: Price for inflation at 6% during 2021, 2022 and 2023 rather than 10%
Solvency position Cost curve
Indexed at January 2019
Ignoring real underling inflation during the pandemic: scheme reaches point of no return within one year
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
1.8
2.0
2019 2020 2021 2022 2023 2024 2025
-40%
-30%
-20%
-10%
0%
10%
20%
30%
40%
50%
60%
2019 2020 2021 2022 2023 2024 2025 2026
Solvency Required solvency
Solvency drops rapidly, with
scheme insolvent by 2024
25% increase in
contributions
required in 2024 to bridge gap
Actuarial death spiral: Young
and healthy drop out by 2025
and sick remain
Contribution increases at 6%: 2021-23	Medical inflation
Underlying medical cost inflation
= 10%
~(CPI+4%)

-- 36 of 71 --

37
SOLVENCY BUILT UP | PROTECTING MEMBERS AND THE SCHEME
SCENARIO 2: DHMS approach to return excess solvency to members through deferrals & WELLTH fund
Solvency position Cost curve
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
1.8
2.0
2019 2020 2021 2022 2023 2024 2025
Jan
-21
Jul-21	
-40%
-30%
-20%
-10%
0%
10%
20%
30%
40%
50%
60%
2019 2020 2021 2022 2023 2024 2025 2026
Solvency Returned to members Required solvency
Deferred contributions & WELLTH
Fund used to return excess solvency
Deferrals
ensured
affordability for
members
Scheme correctly
priced, avoiding any
future price shocks
DHMS contribution deferral strategy	Medical inflation
Jan
-22
Oct
-22
Jan
-23
Apr
-23
Indexed at January 2019
Matching underlying inflation throughout the pandemic: contribution increases less than 10% in all years

-- 37 of 71 --

38
PROTECTING MEMBERS AND THE SCHEME |
Suppressed screening and preventative healthcare during COVID-19
had severe health implications, leaving people with undiagnosed risks
Proportion of eligible members
screening
Preventative screening
materially reduced over
COVID-19
Fewer early-stage cancers
due to a lack of screening
Higher severity at
diagnosis of diabetes
Number of members diagnosed with
cancer
Proportion of new diabetes
diagnoses with complex
conditions
2018 2019 2020 2021 2022
Mammograms
Pap Smear
Prostate Screening
Health Check
Pre-COVID-19 Since COVID-19
Stage 1 Stage 2 Stage 3 Stage 4
-11%
early stage
30.5%
33.5%
Pre-COVID-19 Since COVID-19
+10%
Once-in-lifetime funding to
reset health understanding
R1.4bn
investment in members’ health,
funded by reserves
Up to R10 000 in discretionary wellness
benefits, for all existing and new policies
across all plans

-- 38 of 71 --

39
THE NEED FOR A RESILIENT HEALTHCARE SYSTEM IS MORE APPARENT
THAN EVER
Discovery is supportive of healthcare reform to address
unacceptable levels of inequality in access to quality
healthcare
1
2 The NHI Fund can be a valuable tool to build on public-
private partnerships developed during the COVID-19
pandemic
3
Although the envisaged implementation of NHI is incremental
and long-term, LCBOs present an immediate opportunity
to progress universal health coverage
4
Discovery has proposed a blended funding model, that can
achieve NHI policy objectives with less risk

-- 39 of 71 --

40
Discovery Insure	
Discovery Life	
Discovery Invest	
Discovery Bank	
Discovery Health

-- 40 of 71 --

41
DISCOVERY LIFE
Normalised operating profit New business API Maintained leading market
share position
+30%
to R2 518m
H1
2019
H1
2020
H1
2021
H1
2022
H1
2023
H1
2019
H1
2020
H1
2021
H1
2022
H1
2023
+17%
to R1 485m
NMG Market Share survey Q3 2022
12 months to Sep 2021
27.2%
26.9%
12 months to Sep 2022
Group life returned to
profitability
Individual life: +11%
Life and Invest EV
RoEV annualised
+14.8%
Jun-22 Dec-22
R 38.4bn
R 40.9bn

-- 41 of 71 --

42
POSITIVE CASH GENERATION AND VARIANCES
Premium and Fees
Claims
Operational costs
Cashflows from existing
New business strain
Net Finre
Net Cashflow
Strong cashflow generation
(Life and Invest)
R9 445m
R2 179m
R688m
Persistency
Mortality & Morbidity
Premium & fee income
Other
Total Non-economic
Economic
Total
H1 14	
H2 14	
H1 15	
H2 15	
H1 16	
H2 16	
H1 17	
H2 17	
H1 18	
H2 18	
H1 19	
H2 19	
H1 20	
H2 20	
H1 21	
H2 21	
H1 22	
H2 22	
H1 23
Mortality Morbidity 100%
Positive variances
Discovery Life (Rm) Gross AvE (vs pre-COVID-19 assumptions)
Net of -R163m
morbidity
variance in
Individual Life
R296m Mortality trending to pre-
COVID levels
Elevated morbidity
primarily driven by
increase in volume and
severity of ICB claims
Mortality trending to pre-COVID
levels, elevated morbidity
VNB and margin impacted
by interest rate volatility
and lower volumes*
VNB (Rm)
Life:
VNB margin
(%) Life:
227
169
H1
2022
H1
2023
6.8%
4.5%
H1
2022
H1
2023
*Excludes ACIs and servicing
Cash flow equates to c30% of net
of tax normalised earnings

-- 42 of 71 --

43
None Low-moderate
engagement
High
engagement
Actual H1 2023 Long term expected
None Low-moderate
engagement
High
engagement
Actual H1 2023 Long term expected
POWERFUL SHARED-VALUE DYNAMICS
Based on study by global reinsurer
Comparable portfolio refers to fully underwritten risk providers
87%
144%
103%	100%
186%
123%
Pre-COVID-19 (2015-
2019)
COVID-19 (2020-
2021Q3)
Total (2015-2021Q3)
Discovery Comparable portfolio
-13%
Improved experience dynamics through engagement, consistent with
status-based assumptions
Positive engagement dynamics amplified
through the pandemic
Independent study by global reinsurer confirms lower
relative increase in mortality through COVID-19 period
Lapse experience Mortality experience
*Market comparison from global reinsurer study
20% DSY lower than competitors in a
comparable portfolio* 13% DSY lower than competitors in a
comparable portfolio*
-42%
-20%

-- 43 of 71 --

44
Discovery Insure	
Discovery Life	
Discovery Invest	
Discovery Bank	
Discovery Health

-- 44 of 71 --

45
11%
lower income drawdowns
in shared-value benefits
accrued and paid to
clients
R16.1bn
Since the launch of shared
value:
22%
lower investment lapses
DISCOVERY INVEST
H1
FY 19
H1
FY 20
H1
FY 21
H1
FY22
H1
FY23
+15%
to R592m
Normalised operating
profit
H1
FY 19
H1
FY 20
H1
FY 21
H1
FY22
H1
FY23
-1%
to R1 505m
New business Shared-value
outcomes
0
20
40
60
80
100
120
140
160
180
Discovery Rest of market
Higher net flows
growth than the rest
of the market1
Jul-18
Feb-19	
Sep-19	
Apr-20	
Nov-20	
Jun-21	
Jan-22	
Aug-22
+3%
to R131bn
Assets under
administration
1 Source: ASISA; Retail and funds of funds net flows at 30 September each year rebased at 100 on 30 September 2016
Indexed to 100 at Sept 2016

-- 45 of 71 --

46
COMPELLING BUSINESS CASE
0
20
40
60
80
100
120
140
160
Jan-20
Apr-20
Jul-20
Oct-20	
Jan-21
Apr-21
Jul-21
Oct-21	
Jan-22
Apr-22
Jul-22
Oct-22
Discovery Invest Umbrella Funds
Strong assets under administration
growth
Consistent margin	Leveraging Shared-value model to drive
growth
Discovery Invest
Consistent architecture and Shared-value model	Assets under administration per month Operating profit to assets rebased at 100
Discovery Invest income
protection boosts
Cogence income
protection boosts
0
20
40
60
80
100
120
H1 FY20 H1 FY21 H1 FY22 H1 FY23
Blue
Bronze	
Silver	
Gold
Diamond
+12.5%
+20%
+30%
+40%
+50%
Blue
Bronze	
Silver	
Gold
Diamond
+7.5%
+12.5%
+15%
+20%
+25%

-- 46 of 71 --

47
Discovery Insure	
Discovery Life	
Discovery Invest	
Discovery Bank	
Discovery Health

-- 47 of 71 --

48
Gross new
business
Gross written
premium
to R2 579m1 to R616m2
1 Personal lines figures only
2 Figures excluding VAT
3 Normalised operating profit includes Personal lines but excludes Cambridge Mobile Telematics (CMT), Sigfox and Bi-ME
+3%	+11%
Market share
in GWP
Assuming 6% annual market growth
7%
Vehicles insured
+1%
to 295 066
Normalised
operating profit
to R21m3
-38%
H1
FY19
H1
FY20
H1
FY21
H1
FY22
H1
FY23 H1
FY19
H1
FY20
H1
FY21
H1
FY22
H1
FY23
H1
FY17
H1
FY18
H1
FY19
H1
FY20
H1
FY21
H1
FY22
H1
FY23
H1
FY19
H1
FY20
H1
FY21
H1
FY22
H1
FY23
DISCOVERY INSURE
H1
FY19
H1
FY20
H1
FY21
H1
FY22
H1
FY23

-- 48 of 71 --

49
EXPECT MARGIN RECOVERY AFTER REPRICING ACTION
Model is working
Loss ratio by Vitality
status
Lapses by status
100 89 73 66 57
Blue
Bronze
Silver	
Gold
Diamond
Actual vs motor repair cost
rebased at 100
90
95
100
105
110
115
Jan-20	
May-20	
Sep-20	
Jan-21	
May-21	
Sep-21	
Jan-22	
May-22	
Sep-22
Motor repair cost Premium
Pricing mismatch during
COVID-19
0
50
100
150
200
250
-
500
1 000
1 500
2 000
Q1
FY 21
Q2
FY21
Q3
FY21
Q4
FY21
Q1
FY22
Q2
FY22
Q3
FY22
Q4
FY22
Q1
FY23
Q2
FY23
Load shedding hours
Loss ratio indexed (RHS)
Load shedding impacts on power
surge claims
Proportion of high-risk vehicles in
total claims and new business
Ongoing pressure from
power surge and theft
5% 11% 40% 45%
0%
50%
100%
H2
FY21
H1
FY22
H2
FY22
H1
FY23
Other
High-risk vehicle models
High-risk vehicles NB (rebased)
0
20
40
60
80
100
120
140
Jul-21
Sep-21	
Nov-21	
Jan-22	
Mar-22	
May-22
Jul-22
Sep-22	
Nov-22
Out-of-anniversary
assumption
Actual
Data-driven repricing
action
Lapsed clients have a relatively
higher loss ratio
MTI Lapsed Retained
40%
100 85
57
30 21
Blue
Bronze
Silver	
Gold
Diamond
-10%
-8%
-6%
-4%
-2%
0%
2%
4%
6%
8%
10%
H1
18
H2
18
H1
19
H2
19
H1
20
H2
20
H1
21
H2
21
H1
22
H2
22
H1
23
H2
23
F
Operating profit
glidepath
Forward looking information on this slide is for
illustration and has not been reviewed or reported
on by the auditors

-- 49 of 71 --

50
Vitality Health	
Vitality Car	
Vitality Life
New business
+34%
to R1 691m
Operating profit
+15%
to R1 277m

-- 50 of 71 --

51
UK COMPOSITE
Normalised
operating profit1
Earned premiums Lives covered New business
+16% +11% +15% +35%
to £62.7m to £483.6m to 1.66m lives to £83m
New generation insurer
offering best-in-breed
products across
businesses and operating
as a fully integrated
composite business with a
seamless and intuitive
client journey
Vitality Health	
Vitality Car	
Vitality Life
1 Including Vitality Invest, group initiatives and head office costs
H1
2019
H1
2020
H1
2021
H1
2022
H1
2023
GBP millions
H1
2019
H1
2020
H1
2021
H1
2022
H1
2023
GBP millions
H1
2019
H1
2020
H1
2021
H1
2022
H1
2023
H1
2019
H1
2020
H1
2021
H1
2022
H1
2023
GBP millions

-- 51 of 71 --

52
VITALITY HEALTH
Normalised operating profit Earned premiums Lives covered New business
+3% +26%
to £42.5m to £305.5m to 903k lives to £43.7m
H1
2019
H1
2020
H1
2021
H1
2022
H1
2023
GBP millions
H1
2019
H1
2020
H1
2021
H1
2022
H1
2023
GBP millions
H1
2019
H1
2020
H1
2021
H1
2022
H1
2023
H1
2019
H1
2020
H1
2021
H1
2022
H1
2023
GBP millions
+12% +18%

-- 52 of 71 --

53
Cash from
inforce
book
New
Business
acquisition
New
Projects
Net cash
generated
POSITIVE ACTUARIAL AND OPERATING RESULTS
Good cash generation	Continued excellent
retention strategy
Causal relationship between
engagement and healthcare
costs
Lapse rates Relative healthcare costs by
level of engagement
H1
2018
H1
2019
H1
2020
H1
2021
H1
2022
H1
2023
100
82
84
79 82	82
Musculoskeletal
Oncology
Cardiac
-31%
-37%
-46%
Active Rewards points
£65m
£21.3m
Authorisations returned to
pre-COVID-19 levels
Monthly authorisations per
1000 lives
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
PRE COVID
Jun-20	
Sep-20	
Dec-20	
Mar-21	
Jun-21	
Sep-21	
Dec-21	
Mar-22	
Jun-22	
Sep-22	
Dec-22
Cardiac
Musculoskeletal
Oncology
Mental Health
Total

-- 53 of 71 --

54
WELL POSITIONED FOR FURTHER GROWTH IN THE UK
HEALTHCARE ENVIRONMENT
Greater value placed on PMI cover	Current state of the NHS
Source: The Economist; NHS England; Financial Times
Growth of VH PMI lives
100,000
200,000
300,000
400,000
500,000
600,000
700,000
800,000
900,000
H1
2013
H1
2015
H1
2017
H1
2019
H1
2021
H1
2023
Structural and environmental difficulties
2
3
4
5
6
7
8
Millions
7.1 million
(Nov ‘22)
People waiting to receive treatment
0%
10%
20%
30%
40%
50%
60%
70%
2017 2018 2019 2020 2021 2022
Vitality GP Talking therapies
ODA Physiotherapy
60% in 2022
Percentage of claims that are Primary Care
Surge in demand for Primary Care
services

-- 54 of 71 --

55
IMPROVING THE EFFICIENCY OF HEALTHCARE DELIVERY
Sophisticated analytical, technology and health management assets
Advanced digital pathways.
Intelligent matching with the right
person at the right time
Obtain instant online authorisation
for care digitally through Vitality GP
and Care Hub
Research, compare and book with
highly rated consultants using the
intelligent Consultant Finder tool
Proactive reach-out to members to
assist engaging with Vitality and
accessing healthcare
First insurer to introduce a virtual
GP
Introduced physiotherapy, talking
therapies, optical, dental and
audiology benefits
All accessible via single source
through CareHub
Smart Service – digital-first
engagement journey
Vitality GP Talking Therapies Physiotherapy
>
>
>
>
Expansive primary care.

-- 55 of 71 --

56
VITALITY LIFE
Normalised operating profit Earned premiums Lives covered New business
+49% +45%
to £26.3m to £178.1m to 758k lives to £39.3m
H1
2019
H1
2020
H1
2021
H1
2022
H1
2023
GBP millions
H1
2019
H1
2020
H1
2021
H1
2022
H1
2023
GBP millions
H1
2019
H1
2020
H1
2021
H1
2022
H1
2023
H1
2019
H1
2020
H1
2021
H1
2022
H1
2023
GBP millions
+9% +11%

-- 56 of 71 --

57
STRONG OPERATING PERFORMANCE IN A COMPLEX ECONOMIC
ENVIRONMENT
Exceptional sales
performance despite rising
inflation
Continued excellent
retention strategy
Strong growth in new
business market share
Sales of index-linked policies
rebased to Jan 2022
Lapses AvE Average market share of new
business volumes
Source: NMG UK Risk Distribution Monitor
Intervened against ‘high lapse’ brokers
Restructured franchise channel
Consolidated ops and service at
Group level
Enhanced retention capabilities
Strengthened actuarial bases and set
up COVID-19 provisions
Entered into interest rate hedge
Deferred Part VII transfer
Changed Group legal entity structure
Adapted elements of actuarial
methodology
Sourced liquidity funding in the UK
Area Management actions
1
2
3
4
5
6
7
8
9
10
OPERATIONS
CAPITAL
LIQUIDITY
Addressed the 10-point plan
5.0%
5.5%
6.0%
6.5%
7.0%
7.5%
2020 2021 2022	H1 2019 H1 2020 H1 2021 H1 2022 H1 2023
Expected
-18.8%
CPI
0.0
0.5
1.0
1.5
2.0
2.5
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
Policy sales CPI doubled
since Jan
Policy sales largely
unaffected

-- 57 of 71 --

58
USA
New business*
-12%
to R804m
Operating profit
+33%
to R239m
Income
+69%
to R1 129m
*PAH’s insurance licence business

-- 58 of 71 --

59
Vitality Global
VITALITY GLOBAL
Strong underlying growth, driven by deepened
partner relationships, broadening the reach of
Vitality assets and capabilities
Vitality Network Vitality Health
International
Africa
USA
Operating result
+15%
to $13.8m
+33%
to R239m
Vitality Network
Vitality Health International
H1 2019 H1 2020 H1 2021 H1 2022 H1 2023

-- 59 of 71 --

60
VITALITY NETWORK
Continued growth driven by product innovation, delivery excellence through
Vitality 1 and the deepening of successful partnerships
Vitality Global
Vitality
Network

-- 60 of 71 --

61
VITALITY NETWORK
Integrated API by insurance
partners
Revenue Operating profit Insurance partners
membership
-7%
to $709m
H1
2019
H1
2020
H1
2021
H1
2022
H1
2023
H1
2019
H1
2020
H1
2021
H1
2022
H1
2023
+7%
to R12.3bn
+20%
to $35.3m
+38%
to R613m
+33%
to $11.5m
+52%
to R199m
+24%
to 3.4m
H1
2019
H1
2020
H1
2021
H1
2022
H1
2023
11%
increase
in margin
YoY
H1
2018
H1
2019
H1
2020
H1
2021
H1
2022
H1
2023

-- 61 of 71 --

62
GROWTH SUPPORTED BY ASIAN MARKET RECOVERY POST COVID
AND EXPANSION WITH PARTNERS
1
3 Expansion into South America by enabling a total wellness ecosystem with
Prudential, leveraging the V1 technology
4 A more comprehensive rollout of Vitality with Manulife in Canada
2 Continued success and market expansion with our partners, and a partnership with the
second largest life insurer in India reaching > 43 000 lives in 3 months
Growth in Asian Pacific regions as markets continue to recover from the Pandemic,
with membership growth of 11% for AIA	1

-- 62 of 71 --

63
VITALITY HEALTH INTERNATIONAL
Investment towards growing early growth businesses in
health insurance and health tech in key markets
Vitality Global
Vitality
Network
Vitality Health
International
Africa
USA

-- 63 of 71 --

64
VHI LEVERAGES THE SUCCESS OF THE MATURE PAH TO INVEST
INTO HIGH POTENTIAL HEALTH MARKETS
USA
Operating result
-29%
to $2.3m
-18%
to R40m
Vitality Health
International
Year of launch or
investment by VG
2020
2022
2022
2009
2008
*section follows on slide
AFRICA
HEALTH
Revenue
+99%
to $29.7m
VHI excluding PAH
H1
2019
H1
2020
H1
2021
H1
2022
H1
2023
+13%
VHI
 - Other
 
VHI
 – PAH
includes Amplify Health
revenue from IP fees for
health IP
Including PAH equity earnings
H1
2019
H1
2020
H1
2021
H1
2022
H1
2023

-- 64 of 71 --

65
BROADENING IMPACT & BUILDING GLOBAL DIGITAL HEALTH
CAPABILITIES
Continued expansion into markets and creating partnerships with leading rewards partners
While overall pre-tax profits were down 44% to R624m, PAH licence written premiums for the period increased
14% to R14bn. The decline in overall profits was driven largely by the poor performance of the Shanghai Stock Exchange
causing a 46% decline in investment income
Initial revenue fees from the sale of IP earned in H1 of 2023. Expanding on existing market-leading capabilities
through the acquisition of a Singapore-based leading AI and machine learning solutions provider, with
superior AI solutions & cloud services
Rapid build of health tech capabilities and early positive feedback from market on new capabilities
Following successful solution delivery in Australia, the business is pursuing opportunities to expand into the UK
and Asia
USA
AFRICA
HEALTH

-- 65 of 71 --

66
1.4%
1.7%
1.4%
1.2%
Q1 Q2 Q3 Q4
ECONOMIC ENVIRONMENT IMPACTED BY EXTENSIVE COVID WAVE
First Omicron wave is subsiding	COVID restrictions in place for most
of 2022
Source 1: Local government websites, Gavekal Dragonomics/Macrobond; Source 2: Reuters; Source: 3 Wu Zunyou, the chief epidemiologist at the China Center for Disease Control, Reuters 21 January; Source 4: New York Times, 15 February – models based on 1) the prior Shanghai outbreak, 2) travel patterns 4) recent testing
data 4) US death rate; Source 5 Bernhard Schwartländer, epidemiologist; Source 6: CCDC. Source 7: Economist Intelligence Unit, January 2023
Economic environment expected to
rebound7
• Population infection rate: ~80%3
• Official cumulative deaths: 83,1504
• Estimated cumulative deaths: 500k – 1.5m4,5
• Peak COVID hospitalisations: 1.625m (5 Jan
23)6
0
500000
1000000
1500000
2000000
2500000
3000000
3500000
01/07/2022 01/08/2022 01/09/2022 01/10/2022 01/11/2022 01/12/2022 01/01/2023 01/02/2023 01/03/2023
31-03-23	01-07-22
3.5mn
01-10-22 01-01-23
• Restrictions varied from city-wide lockdowns to
more open movement with 72-hour PCR testing
• Rapid removal of restrictions in December
and now completely lifted
• 308m domestic tourism trips during Lunar
new year2
GDP growth performance
2023 GDP growth forecast
(%change QoQ)
Driven by
consumption
and
investment
0.00
0.25
0.50
0.75
1.00
1.25
1.50
1.75
2.00
Jan	
Feb
Mar
Apr
May
Jun	
Jul
Aug
Sep
Oct
Nov
Dec
Jan-23
Shanghai in
full lockdown Shanghai
starts to
reopen
“10 new measures”
to ease policy
“20 new measures”
to ease policy
Protests
Official downgrading
of Covid response
Quarantine for int’l
arrivals dropped
Lockdown intensity index in top 100 Cities (GDP
weighted)1
Projected daily COVID-19 infections (IHME)
2018 2019 2020 2021 2022 2023 2024
Actual Forecast
3.0%
5.7%
01-22 01-23

-- 66 of 71 --

67
H1
2019
H1
2020
H1
2021
H1
2022
H1
2023
PAH licence Reinsurance
H1
2019
H1
2020
H1
2021
H1
2022
H1
2023
Investment income and gains
Profit before investment income and gains
PING AN HEALTH
PAH’s operating results pre-
tax
Discovery’s operating
result after tax
Written premium1 New business1
-44% -40% +0% -37%
to R624m
(DSY’s share is R107m)
to R84m R20.4bn to R3.6bn
1 100% of PAH
H1
2019
H1
2020
H1
2021
H1
2022
H1
2023
H1
2019
H1
2020
H1
2021
H1
2022
H1
2023
PAH licence Reinsurance
-46%
growth in
investment
income
-12%
growth in
PAH licence
business
+14%
growth in PAH
licence written
premium
-37%

-- 67 of 71 --

68
Q1 Q2 Q3 Q4
Investment income
Q1 Q2 Q3 Q4
Profit from operations
PING AN HEALTH REMAINS RESILIENT SUPPORTED BY STRONG
BUSINESS FUNDAMENTALS
High quality metrics	Profits impacted by negative investment performance
and conservative reserving approach
* As defined by the China Banking and Insurance Regulatory Commission
93.6%
Combined
Operating
Ratio
219%
Core
solvency
ratio*
266%
Comprehensive
solvency
ratio*
RMB11bn
Insurance
contract
reserves as at
31 Dec 2022

-- 68 of 71 --

69
RAPID ESTABLISHMENT OF LEADING DIGITAL HEALTH SOLUTIONS
ACCELERATED BY A SUCCESSFUL ACQUISITION OF AIDA
1
3 Acquisition of AiDA accelerating expansion in Asia and provides commercially
proven solutions with strong synergies with Amplify Health IP
4 7 products identified for development, with 3 prioritised (Smart Claims, Chronic
Disease Management platform and Data Foundation) due to clear demand from local
markets
2 Transfer of IP and talent is largely complete with leadership and management roles
fully staffed
Revenue and capital model appropriate and fit for expansion: up to $200m of build
and acquisition costs funded in return for IP and talent transfer	1
5 Positive discussions being held with 4 markets and early-stage interest shown by
various private healthcare businesses including large regional hospital groups

-- 69 of 71 --

70
GLOBAL
Core new
business
+15%
to R11 061m
Normalised
headline earnings
+30%
to R3 747m
Headline
earnings
-9%
to R2 981m
1
2
3
Evolving the model to create a platform for strong future growth
Strong growth in quality earnings, driven by the efficacy of the Vitality
shared-value model and in line with the target operating model
Focus on financial prudence and immunisation from a volatile interest rate
environment
4
Strong performance removes need for VCP; and given strong growth dynamics
a dividend is premature but will be revisited at the end of the financial year
Normalised
operating profit
+22%
to R5 930m
Total income from
non-insurance
+51%
to R2 528m

-- 70 of 71 --

Discovery Limited
Copyright © Discovery Ltd is the licensed controlling company of the designated Discovery Insurance Group. Registration number: 1999/007789/06.
Companies in the Group are licensed insurers and authorised financial services providers.

-- 71 of 71 --